Key Questions on COVID-19 and Cardiovascular Disease

The following is a digest of ACC’s clinical guidance on the cardiac implications of COVID-19. Organized in an FAQ format for easy navigation, this guidance is summarized from more extensive documents approved by the ACC Science and Quality Committee and published on the ACC Covid-19 Hub or in the Journal of the American College of Cardiology. This FAQ document is intended to be topical, not comprehensive.

CONTENTS
1. What is the role of troponin measurement in COVID-19?
2. What is the role of BNP measurement in COVID-19?
3. What is the role of RAAS inhibitors in COVID-19?
4. What is the role of statin therapy in COVID-19?
5. What are some considerations for echocardiography in COVID-19?
6. What are some considerations around older adults with cardiovascular disease in COVID-19?
7. What are the QT-monitoring considerations for hydroxychloroquine and azithromycin use in COVID-19?
8. How should patients with cardiovascular conditions manage workplace exposure to COVID-19?
9. What are thrombosis risk and management considerations in COVID-19?
10. How should AMI be managed during COVID 19?
11. What are the considerations for cardiomyopathy and heart failure in COVID-19?
WHAT IS THE ROLE OF TROPONIN MEASUREMENT IN COVID-19?

Category: Biomarker Management
Patient Type: COVID+
Prevalence: COMMON
Principal Guidance: Troponin is commonly elevated in patients COVID-19 and does necessarily indicate myocardial infarction (MI) or other cardiac sequelae; routine monitoring of troponin is indicated upon clinical suspicion of MI or cardiac dysfunction.

Author: James L. Januzzi, Jr., MD, FACC
Source: Troponin and BNP Use in COVID-19
SQC Approval Date: March 18, 2020

Rise and/or fall of troponin – indicating myocardial injury – is common among patients with acute respiratory infections and correlates with disease severity. Abnormal troponin values are common among those with COVID-19 infection particularly when a high sensitivity cardiac troponin (hs-cTn) assay is used. Detectable hs-cTn is observed in most patients with COVID-19 and significantly elevated in more than half of the patients who died.

The mechanisms underlying myocardial injury in those with COVID-19 infection are not fully understood, however in keeping with other severe respiratory illnesses, direct (“non-coronary”) myocardial damage is almost certainly the most common cause. Given the presence of abundant distribution of ACE2 – the binding site for the SARS-CoV-2 in cardiomyocytes – some have postulated that myocarditis might be a common cause. Support for this comes from reports of COVID-19-related acute left ventricular failure. Other possibilities include acute MI – either Type 1 MI based on plaque rupture triggered by the infection or Type 2 MI based on supply-demand inequity. Importantly, a rise and/or fall of troponin is insufficient to secure the diagnosis of acute MI; rather, it should be based on clinical judgment, symptoms and signs, and ECG changes.

Given the frequency and nonspecific nature of abnormal troponin results among patients with COVID-19 infection, clinicians are advised to only measure troponin if the diagnosis of acute MI is being considered on clinical grounds. In addition, an abnormal troponin should not be considered evidence for an acute MI without corroborating evidence.

Use of echocardiography or coronary angiography for COVID-19 patients with myocardial injury or elevated troponin should be restricted to those in whom additional diagnostics would meaningfully affect clinical outcomes.
WHAT IS THE ROLE OF BNP MEASUREMENT IN COVID-19?

Category: Biomarker Management
Patient Type: COVID+
Prevalence: COMMON

Principal Guidance: BNP is commonly elevated in patients with COVID-19 and does not necessarily indicate new onset heart failure; evaluation and treatment for heart failure should only be initiated in COVID-19 patients with elevated BNP in the presence of confirmatory clinical evidence.

Author: James L. Januzzi Jr., MD, FACC
Source: Troponin and BNP Use in COVID-19
SQC Approval Date: March 18, 2020

Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses, typically in the absence of elevated filling pressures or clinical heart failure. Much like troponin, elevation of BNP or NT-proBNP is associated with an unfavorable course among patients with ARDS. Patients with COVID-19 infection often demonstrate significant elevation of BNP or NT-proBNP levels. The significance of this finding is uncertain and should not trigger an evaluation or treatment for heart failure unless there is clear clinical evidence for the diagnosis.

Use of echocardiography or coronary angiography for COVID-19 patients with myocardial injury or elevated natriuretic peptides should be restricted to those in whom additional diagnostics would meaningfully affect clinical outcomes.

WHAT IS THE ROLE OF RAAS INHIBITORS IN COVID-19?

Category: CV Therapeutics
Patient Type: All
Prevalence: COMMON

Principal Guidance: ACC, AHA, HFSA and ESC all strongly recommend continuation of ACE/ARB/ARNIs in accordance with current clinical guidelines regardless of COVID status unless clinically warranted (i.e., hemodynamic management in acute care context).

Author: ACC, AHA, HFSA
Source: HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
SQC Approval Date: March 17, 2020

Currently there are no experimental or clinical data demonstrating beneficial or adverse outcomes with background use of ACE inhibitors, ARBs or other RAAS antagonists in COVID-19 or among COVID-19 patients with a history of cardiovascular disease treated with such agents. The HFSA, ACC and AHA recommend continuation of RAAS antagonists for those patients who are currently prescribed such agents for indications for which these agents are known to be beneficial, such as heart failure, hypertension or ischemic heart disease. In the event patients with cardiovascular disease are diagnosed with COVID-19, individualized treatment decisions should be made according to each patient’s hemodynamic status and clinical presentation. Therefore, be advised not to add or remove any RAAS-related treatments, beyond actions based on standard clinical practice.
WHAT IS THE ROLE OF STATIN THERAPY IN COVID-19?

Category: CV Therapeutics
Patient Type: All
Prevalence: COMMON

Principal Guidance: Guideline-directed statin therapy is critical in the context of COVID-19 given the high mortality amongst patients with preexisting cardiometabolic disease; limited evidence suggests statin therapy may mitigate cardiovascular events among patients with viral infections, but is insufficient to warrant COVID-specific prescribing.

Author: Salim Virani, MD, FACC
Source: Is there a role for statin therapy in acute viral infection?

SQC Approval Date: March 18, 2020

Guideline-directed statin therapy in patients with clinical ASCVD, diabetes, or those at moderate-to-high risk remains critical in the COVID-19 context given the extremely high case fatality rate for patients with cardiovascular disease (10.8%) and diabetes (7.3%). Some observational studies also suggest that statin therapy is associated with a reduction in various cardiovascular outcomes (and potentially mortality) among hospitalized patients with influenza and/or pneumonia.

One randomized trial suggested possible beneficial effects of initiating oral statin therapy for intubated pneumonia cases; another trial did not find benefit. Nonetheless, these findings have been used to hypothesize a potentially beneficial effect of statins for patients with MERS-COV (and other beta coronaviruses like SARS-CoV-2). Currently no randomized or observational evidence to supports these conjectures. Importantly, however, statins do not appear to be harmful in this setting.
WHAT ARE SOME CONSIDERATIONS FOR ECHOCARDIOGRAPHY IN COVID-19?

**Category:** IMAGING  
**Patient Type:** COVID+  
**Prevalence:** COMMON  

**Principal Guidance:** Point-of-care ultrasound, with ultrasound enhancing agent as required, is the preferred frontline imaging modality for COVID+ patients because it provides clinically meaningful information, serves as effective triage for more advanced imaging, and minimizes staff exposure.

**Author:** James Kirkpatrick, MD, FACC, FASE (Chair); Carol Mitchell, PhD, FASE; Cynthia Taub, MD, FASE; Smadar Kort, MD, FACC, FASE; Judy Hung, MD, FACC, FASE; Madhav Swaminathan, MD, FASE  

**Source:** ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak  

**SQC Approval Date:** March 18, 2020

Echocardiography is an essential imaging modality to assess cardiac complications of viral infection as well as manage COVID+ patients with underlying cardiovascular disease. However, in the context of infectious disease, modifications of standard procedure may be warranted.

- Point-of-care ultrasound (POCUS) may be advisable for COVID+ patients because it allows in-room patient evaluation while minimizing staff exposure. When possible, pre-plan procedures, including the use of ultrasound enhancing agent (UEA), to rapidly acquire the most relevant sequence of images. UEA have been proved safe and effective in ICU patients. Archiving and transmitting images to experienced echocardiographers may obviate the need for additional echoes and/or accurately guide the clinical need for advanced imaging (e.g., wall motion, quantitative valvular assessment, etc.).

- Contrast enhanced computed tomography and MR should be considered as alternatives to aerosol-inducing TEE for exclusion of left atrial appendage thrombus prior to cardioversion.

- Consider deferring stress echoes or utilizing an alternative modality given the additional transmission risk associated with deep breathing and potential cough.

- As with all procedures, special attention should be given to matching PPE with risk and rigorously cleaning and disinfecting equipment between patients.
WHAT ARE SOME CONSIDERATIONS AROUND OLDER ADULTS WITH CARDIOVASCULAR DISEASE IN COVID-19?

Category: RESOURCE MANAGEMENT
Patient Type: COVID+ CV, COVID- CV
Prevalence: COMMON

Principle Guidance: Older adults with cardiovascular disease are at risk for both severe presentation of COVID-19, and lack of adequate cardiovascular disease monitoring during the pandemic. Cardiologists can consider these practical management strategies to facilitate care.

Author: Nicole M. Orr, MD, FACC, and select members of the ACC Geriatric Member Section

Source: Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic

SQC Approval Date: April 24, 2020

Many older adults fearful of COVID-19 are strictly adherent to social isolation measures and may be avoiding routine medical care. Continued management of cardiac disease during the pandemic is essential as optimization of cardiovascular health may not only decrease the risk of a cardiac admission but potentially mitigate vulnerability if exposed to SARS-CoV-2. Patients should be contacted to avoid canceling appointments and encouraged to reschedule via telehealth encounters when feasible. Older adults may have difficulty navigating audio-visual technology, so patients and families should be encouraged to familiarize themselves with a video platform to which they have access and feel comfortable using. Telephone visits should be maintained and will be reimbursed if patients cannot or do not wish to use video technology.

Encounters with noninfected older adults during the pandemic should focus on disease prevention and COVID-19 preparation.

1. Safeguarding measures should be reiterated at every opportunity, and clinicians should utilize the teach-back method to ensure understanding.

2. Direct encounters with high-risk older adults should be proactively avoided by clinicians if they have recent significant COVID exposure despite lack of symptoms.

3. All relevant guideline-directed medication therapy should be continued in the absence of contraindications; it is reasonable to consider initiating statin therapy according to ACC guidelines.
4. The importance of maintaining nutrition, hydration and daily exercise despite social isolation measures should be emphasized.

5. Older adults should be instructed to identify a healthy, low risk, trusted point-of-contact with whom physicians can maintain communication.

6. All older adults should be strongly encouraged to prepare advance directives and clarify religious preferences prior to potential SARS-CoV-2 infection in order to make treatment decisions at the time of potential illness concordant with their goals.

COVID-19 disease management in older adults should be individualized as older adults are heterogeneous with respect to health status and resiliency; chronologic age alone should not determine management strategy.

1. Pharmacologic management for eligible older adults should follow guidelines outlined by the CDC. In particular, the efficacy of hydroxychloroquine and chloroquine remain unproven and optimally should be administered within clinical research protocols and monitored carefully given the increased QT prolongation risk.

2. Patients should be informed that hospitalization and recovery will be challenging given isolation requirements.

3. Patients should be instructed to identify a caregiver to assist in recovery if sent home, and prepare means to maintain social connections (e.g., FaceTime, family chat rooms, etc.) to help ease the emotionally challenging experience of isolated recovery in a skilled nursing facility.

WHAT ARE THE QT-MONITORING CONSIDERATIONS FOR HYDROXYCHLOROQUINE AND AZITHROMYCIN USE IN COVID-19?

Category: Experimental COVID Therapeutics
Patient Type: COVID+
Prevalence: COMMON

Principal Guidance: QT-prolonging medications, including those used for COVID, require assessment and management of ventricular arrhythmia risk. Until clinical trial guidance is available, a standard approach that has been modified for pandemic exigencies is outlined.

Author: Timothy F. Simpson, MD, PharmD; Richard J. Kovacs, MD, MACC; Eric C. Stecker MD, FACC
Source: Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19
SQC Approval Date: March 29, 2020

In vitro and preliminary clinical research has suggested that hydroxychloroquine alone and in combination with azithromycin could be an effective treatment for COVID-19. Although clinical evidence remains nascent, clinicians in many countries have begun using these medications. However, chloroquine, hydroxychloroquine and azithromycin all prolong the QT interval, raising concerns about the risk of arrhythmic death from individual or concurrent use of these medications. We strongly encourage enrollment of patients in clinical research protocols, whenever available. All clinical use that occurs outside of a research setting should incorporate anticipated benefits balanced against risks. As additional research results become available, recommendations for QT monitoring may escalate or de-escalate.
HOW SHOULD PATIENTS WITH CARDIOVASCULAR CONDITIONS MANAGE WORKPLACE EXPOSURE TO COVID-19?

Category: CV THERAPEUTICS
Patient Type: COVID- CV
Prevalence: COMMON

Principal Guidance: Clinicians should counsel patients with preexisting cardiovascular conditions to take extra precautions, including in the workplace, to minimize exposure risk to COVID-19.

Author: Joseph Marine, MD, FACC; Daniel M. Philbin, Jr., MD, FACC; Kim A. Eagle, MD, MACC; and Thomas M. Maddox, MD, MSc, FACC

Source: Standalone

SQC Approval Date: April 24, 2020

Patients with cardiovascular conditions, especially poorly controlled disease, are at higher risk for COVID-19 complications. As such, they should be counseled to avoid situations that would put them at risk for SARS CoV2 exposure. They, along with their physician, should evaluate their workplace and determine if undue risk exists. If so, mitigation strategies should be considered. These include minimizing face-to-face contact between employees, assigning work tasks that allow the patient to maintain six-foot distance from other workers, customers and visitors, or to telework if possible. For patients who work in health care settings, avoidance of direct COVID-19 patient exposure should be attempted. In addition, they should be assured of adequate personal protective equipment appropriate to their work environment.

Please refer to the CDC recommendations regarding workplace accommodations, found here: https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-business-response.html
WHAT ARE THROMBOSIS RISK AND MANAGEMENT CONSIDERATIONS IN COVID-19?

Category: COVID THERAPEUTICS
Patient Type: COVID+
Prevalence: MODERATELY COMMON

Principal Guidance: The apparent increased thrombotic risk in COVID-19 patients is sufficient to recommend pharmacological VTE prophylaxis in all hospitalized patients unless contraindicated; D-dimer levels may be valuable for clinical monitoring, but there is currently no evidence supporting its use to guide anticoagulation intensity beyond clinical judgment; post-discharge VTE prophylaxis with a DOAC should be considered.

Author: Geoffrey D. Barnes, MD, MSc, FACC; Adam Cuker, MD, MS; Ty J. Gluckman, MD, FACC; Gregory Piazza MD, MS, FACC; Deborah M. Siegal MD, MSc

Source: Thrombosis and COVID-19: FAQs for Current Practice
SQC Approval Date: April 22, 2020

Despite the limited published evidence, most experts agree that the signal for increased thrombotic risk is sufficient to recommend pharmacologic venous thromboembolism (VTE) prophylaxis in all hospitalized COVID-19 patients as long as there is no contraindication. When clinically appropriate, once daily low-molecular weight heparin may help minimize staff exposure risk and conserve personal protective equipment (PPE). The coagulopathy found in severe COVID-19 appears to be associated with normal or increased fibrinogen levels, unlike disseminated intravascular coagulopathy (DIC), and thus does not present a clear increased risk for bleeding.

High D-dimer levels appear to predict a poor prognosis in COVID-19 patients, although the relationship between elevated D-dimer levels and mortality has been shown in previous cohorts of critically ill patients. Therapeutic anticoagulation is not mandatory for all patients based only on an elevated D-dimer test and there is no evidence supporting use of D-dimer values to guide intensity of anticoagulation. However, D-dimer values may be helpful for clinical monitoring, characterizing the coagulopathy, and conducting clinical trials to rigorously test management strategies. Use of higher-intensity, non-standard VTE prophylaxis can be considered for patients with COVID-19, but ideally should be done within the context of a clinical trial given current lack of efficacy evidence.

Assessment for VTE should incorporate multiple elements of the patient condition, including interval history, physical exam and vital signs, currently administered treatments, and laboratory studies. The decision to order imaging for VTE should not be based on an elevated D-dimer alone. Targeted imaging to confirm suspected VTE and guide therapeutic anticoagulation is preferred if it can be performed with acceptable exposure risk.

Post-hospital VTE prophylaxis should be considered in patients with COVID-19 given the long duration of the illness and the increased likelihood of immobility and superinfection. Experience from several studies suggests that in select patients without COVID-19, post-discharge thromboprophylaxis (particularly with a DOAC) may be beneficial if bleeding risk can be minimized. Use of a validated risk score (e.g., IMPROVE or IMPROVEDD score with D-dimer) may be particularly helpful in guiding decision-making.
HOW SHOULD AMI BE MANAGED DURING COVID-19?

Category: CV THERAPEUTICS
Patient Type: ALL
Prevalence: MODERATELY COMMON
Principal Guidance: All attempts should be made to maintain the current AMI standard of care; additional evaluation may be warranted to accurately assess COVID status and MI etiology to better manage exposure risk and guide appropriate treatment.

Author: Consensus statement of SCAI, ACC, and ACEP
Source: Management of Acute Myocardial Infarction During the COVID-19 Pandemic
SQC Approval Date: April 20, 2020

Cardiovascular manifestations in the COVID-19 patient are complex: patients may present with acute myocardial infarction (AMI), myocarditis simulating a STEMI presentation, stress cardiomyopathy, nonischemic cardiomyopathy, coronary spasm, or myocardial injury without a documented Type I or Type II AMI, requiring careful diagnostic differentiation to maximize therapeutic effectiveness and minimize unnecessary medical staff exposure risk. Nonetheless, most AMI cases in the U.S. remain COVID- and should be managed for expedient revascularization according to standard PCI protocols. Fibrinolysis-based reperfusion strategy may be appropriate in non-PCI capable hospitals, especially when timely transfer is not practical, or when otherwise clinically indicated.

• AMI standard-of-care during COVID-19: All efforts should be made to maintain the current AMI standard-of-care. Door-to-balloon times remain important and should continue to be measured, however additional time may be required for careful clinical differentiation of both COVID status and precise MI etiology to minimize exposure risk and ensure the appropriate therapeutic intervention. AMI management protocols in the context of pandemic COVID-19 should be developed in advance, and include EMS, the ED, and the cardiac catheterization laboratory (CCL). Dedicated COVID-19 CCLs and PPE should be available in geographies with widespread community transmission.

• Definite STEMI: Primary PCI within 90 minutes remains the standard-of-care in PCI capable hospitals regardless of COVID status. Additional exposure precautions are mandatory in probable and confirmed COVID-19 patients, but may be considered for all cases given asymptomatic presentation and the potential for false-negative COVID test results.

• Possible STEMI: For patients who have an unclear, or equivocal, diagnosis of STEMI due to atypical symptoms, diffuse ST-segment elevation or atypical ECG findings, or a delayed presentation, additional noninvasive evaluation in the ED is recommended. The focus of this evaluation is further risk stratification for COVID-19 status and further evaluation of the potential for coronary thrombotic occlusion versus other pathologies.

• Futile prognosis: Not all COVID-19 patients with ST elevation with/without an acute coronary occlusion will benefit from any reperfusion strategy or advanced mechanical support. In COVID-19 confirmed patients with severe pulmonary decompensation (adult respiratory distress syndrome) or pneumonia who
are intubated in the ICU and felt to have an excessively high mortality, consideration for compassionate medical care may be appropriate.

- **Non-STEMI capable referral hospitals**: Primary PCI remains the standard of care for patients transferred rapidly from non-PCI centers (within 120 minutes of first medical contact at Referral Hospital). For patients in whom rapid reperfusion with primary PCI is not feasible, a pharmacoinvasive approach is recommended with initial fibrinolysis followed by consideration of transfer to a PCI center. The COVID status of the individual patient, along with the COVID burden at both the referring and receiving hospital may require modifications to this standard.

- **Cardiogenic shock and/or out-of-hospital cardiac arrest**: Patients with resuscitated out-of-hospital cardiac arrest (OHCA) and/or cardiogenic shock will continue to be the highest risk subgroup of AMI patients. These patients will also be the highest risk for droplet-based spread of COVID-19. Patients with resuscitated OHCA should be selectively considered for CCL activation in the presence of persistent ST-elevation on their electrocardiogram, and a concomitant wall motion abnormality on echocardiographic evaluation.

- **Non-ST elevation AMI**: Standard of care to both COVID positive and negative patients. COVID-19 positive or probable patients with an NSTEMI presentation should be managed medically and only taken for urgent coronary angiography and possible PCI in the presence of high-risk clinical features (Global Registry of Acute Coronary Events [GRACE] score >140) or hemodynamic instability.
WHAT ARE THE CONSIDERATIONS FOR CARDIOMYOPATHY AND HEART FAILURE IN COVID-19?

Category: COVID THERAPEUTICS
Patient Type: COVID+
Prevalence: MODERATELY COMMON

Principal Guidance: Cardiac dysfunction is moderately common among hospitalized patients with COVID-19 and confers a worse prognosis; focused imaging and other cardiac diagnostics are warranted to guide differential management, but must be balanced against exposure risk; clinical management remains supportive although experimental strategies are being evaluated.

Author: Joel D. Schilling, MD, PhD; Ashwin K. Ravichandran, MD, FACC; Stacy A. Mandras, MD, FACC

Source: Management of the Hospitalized COVID-19 Patient with Acute Cardiomyopathy or Heart Failure

SQC Approval Date: April 16, 2020

Cardiovascular involvement is common in patients with severe COVID-19 disease and is associated with a worse prognosis. Those with underlying cardiovascular disease are particularly susceptible to cardiovascular complications and mortality with COVID-19, thus reinforcing the importance of continuing guideline-directed medication therapy in hemodynamically stable ambulatory patients without contraindications.

In severe COVID-19 cases, cardiomyopathy may result from SARS-CoV-2-induced myocarditis, profound systemic inflammation, and/or microvascular dysfunction. There is currently very little data to guide the optimal management of patients with COVID-19 disease who develop cardiomyopathy or mixed cardiogenic shock. Cardiac imaging may be useful, but only when testing is likely to result in differential management and exposure risk can be adequately mitigated.

• In patients hospitalized with COVID-19 cardiac biomarkers should be checked on admission and in follow-up approximately 24-48 hours later.
• Myocarditis or inflammatory cardiac dysfunction should be considered in patients with COVID-19 who have elevated cardiac biomarkers and worsening hemodynamics or arrhythmias.
• ECG should be employed to screen for evidence of ST-T wave changes.
• Maintain a low threshold for POCUS in patients with the above clinical features.
• If evidence of cardiac dysfunction, consider select view for transthoracic echocardiography (TTE) to define LV/RV size and function, wall motion abnormalities, and/or pericardial effusion.
• Stable patients with suspected cardiovascular involvement should continue on guideline-directed medical therapy for heart failure.
In patients with refractory shock, consider pulmonary artery catheters to help guide the use of inotropes, vasopressors or mechanical support.

Endomyocardial biopsy may have a role in select patients being considered for clinical trials of anti-inflammatory therapy.

The mainstay of managing patients with severe COVID-19 disease who have cardiac involvement is supportive care. There is currently no evidence to direct the management of these patients differently than any other inflammatory or “mixed” shock state. Experimental strategies including antiviral, anti-inflammatory, convalescent sera are being considered as part of research protocols or compassionate use for COVID-19 infection with or without cardiac involvement.